551 related articles for article (PubMed ID: 28600189)
1. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CR; Clegg S; Nielsen C; Fox NC; Wilkie D; Nicholas JM; Calder VL; Greenwood J; Frost C; Nicholas R
Lancet; 2014 Jun; 383(9936):2213-21. PubMed ID: 24655729
[TBL] [Abstract][Full Text] [Related]
3. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
van der Vaart T; Plasschaert E; Rietman AB; Renard M; Oostenbrink R; Vogels A; de Wit MC; Descheemaeker MJ; Vergouwe Y; Catsman-Berrevoets CE; Legius E; Elgersma Y; Moll HA
Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
[TBL] [Abstract][Full Text] [Related]
5. Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.
Williams TE; Holdsworth KP; Nicholas JM; Eshaghi A; Katsanouli T; Wellington H; Heslegrave A; Zetterberg H; Frost C; Chataway J
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35031587
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: Treatment of cognitive impairment in secondary progressive MS.
Feinstein A
Nat Rev Neurol; 2017 Sep; 13(9):515-516. PubMed ID: 28752856
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
[TBL] [Abstract][Full Text] [Related]
8. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.
Needham DM; Colantuoni E; Dinglas VD; Hough CL; Wozniak AW; Jackson JC; Morris PE; Mendez-Tellez PA; Ely EW; Hopkins RO
Lancet Respir Med; 2016 Mar; 4(3):203-12. PubMed ID: 26832963
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
[TBL] [Abstract][Full Text] [Related]
12. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
13. Relationship between Social Cognition and traditional cognitive impairment in Progressive Multiple Sclerosis and possible implicated neuroanatomical regions.
Ciampi E; Uribe-San-Martin R; Vásquez M; Ruiz-Tagle A; Labbe T; Cruz JP; Lillo P; Slachevsky A; Reyes D; Reyes A; Cárcamo-Rodríguez C
Mult Scler Relat Disord; 2018 Feb; 20():122-128. PubMed ID: 29414284
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.
Huang G; Wharton W; Bhasin S; Harman SM; Pencina KM; Tsitouras P; Li Z; Hally KA; Asthana S; Storer TW; Basaria S
Lancet Diabetes Endocrinol; 2016 Aug; 4(8):657-665. PubMed ID: 27377542
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
17. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
18. Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment.
Resnick SM; Matsumoto AM; Stephens-Shields AJ; Ellenberg SS; Gill TM; Shumaker SA; Pleasants DD; Barrett-Connor E; Bhasin S; Cauley JA; Cella D; Crandall JP; Cunningham GR; Ensrud KE; Farrar JT; Lewis CE; Molitch ME; Pahor M; Swerdloff RS; Cifelli D; Anton S; Basaria S; Diem SJ; Wang C; Hou X; Snyder PJ
JAMA; 2017 Feb; 317(7):717-727. PubMed ID: 28241356
[TBL] [Abstract][Full Text] [Related]
19. Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.
De Giglio L; Marinelli F; Barletta VT; Pagano VA; De Angelis F; Fanelli F; Petsas N; Pantano P; Tomassini V; Pozzilli C
CNS Drugs; 2017 Feb; 31(2):161-168. PubMed ID: 27995531
[TBL] [Abstract][Full Text] [Related]
20. [Information processing speed and influential factors in multiple sclerosis].
Zhang ML; Xu EH; Dong HQ; Zhang JW
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(15):1173-7. PubMed ID: 27117362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
